首页> 外文期刊>The Journal of Urology >Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation.
【24h】

Intravesical suplatast tosilate (IPD-1151T) inhibits experimental bladder inflammation.

机译:膀胱内suplateast甲苯磺酸盐(IPD-1151T)抑制实验性膀胱炎症。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Interstitial cystitis is a painful bladder disease characterized by urgency, frequency and variable inflammation but there is no curative therapy. Suplatast tosilate (IPD-1151T) is an immunoregulatory compound that decreases interstitial cystitis symptoms but to our knowledge its mechanism of action is unknown. We investigated the effect of intravesical IPD-1151T on mediator release from bladder explants in experimental cystitis. MATERIALS AND METHODS: A catheter was inserted into the bladder of female mice. After urine was emptied normal saline, carbachol (100 nM) or lipopolysaccharide (10 mg/ml) was introduced with or without 10-minute pretreatment with IPD-1151T. Urine was removed after 45 minutes for histamine and tumor necrosis factor-alpha assays. The bladder was removed after 4 hours, minced into 1 mm2 pieces and cultured with or without triggers overnight for mediator release. The effect of IPD-1151T was also tested on rat skin vascular permeability as well as on purified rat peritoneal mast cells and human cord blood derived mast cells. RESULTS: Carbachol significantly increased histamine release in urine (61.3% in 8 preparations, p<0.05) but not in explant medium. IPD-1151T inhibited this effect by 77%. Lipopolysaccharide induced a 350% urine histamine increase in 9 preparations (p<0.05) and a 300% tumor necrosis factor-alpha increase in explant medium. IPD-1151T inhibited the lipopolysaccharide induced medium tumor necrosis factor-alpha increase by 95% in 5 preparations (p<0.05). IPD-1151T did not inhibit rat skin vascular permeability or purified rat peritoneal mast cell activation by compound 48/80 or human cord blood derived mast cells by anti-IgE. CONCLUSIONS: IPD-1151T inhibits bladder release of histamine and tumor necrosis factor-alpha through a mechanism that does not appear to involve direct mast cell inhibition. These findings may justify a beneficial effect of IPD-1151T in interstitial cystitis.
机译:目的:间质性膀胱炎是一种痛苦的膀胱疾病,其特征是紧迫,频繁和发炎,但尚无治疗方法。 Suplatast Tosilate(IPD-1151T)是一种免疫调节化合物,可减少间质性膀胱炎的症状,但据我们所知其作用机理尚不清楚。我们调查了膀胱内IPD-1151T对实验性膀胱炎中膀胱外植体中介质释放的影响。材料与方法:将导管插入雌性小鼠的膀胱。排空尿液的生理盐水后,在不使用IPD-1151T进行10分钟预处理的情况下,加入卡巴胆碱(100 nM)或脂多糖(10 mg / ml)。 45分钟后取出尿液进行组胺和肿瘤坏死因子-α检测。 4小时后取出膀胱,切成1mm2的小块,并在有或没有触发器的情况下培养过夜以释放介体。还测试了IPD-1151T对大鼠皮肤血管通透性以及纯化的大鼠腹膜肥大细胞和人脐血来源的肥大细胞的作用。结果:卡巴胆碱显着增加了尿液中组胺的释放(8种制剂中组胺的释放率为61.3%,p <0.05),而在外植体培养基中则没有。 IPD-1151T抑制了77%。在9种制剂中,脂多糖诱导尿中组胺增加350%(p <0.05),在外植体培养基中引起300%肿瘤坏死因子-α增加。 IPD-1151T在5种制剂中抑制了脂多糖诱导的中等肿瘤坏死因子-α的含量增加了95%(p <0.05)。 IPD-1151T不会通过化合物48/80抑制大鼠皮肤血管通透性或纯化的大鼠腹膜肥大细胞活化,也不会通过抗IgE抑制人脐带血来源的肥大细胞。结论:IPD-1151T通过不涉及直接肥大细胞抑制的机制抑制组胺和肿瘤坏死因子-α的膀胱释放。这些发现可能证明IPD-1151T在间质性膀胱炎中具有有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号